

Enabling Resources for Treatment Decisions in Prostate Cancer Survivors:

Findings from the Prostate Cancer Registry

Kimberly E. Davis, Ph.D.; Reginald Gooden MPH; Blake Watts; Shafiq A. Khan, Ph.D.

Center for Cancer Research and Therapeutic Development (CCRTD)
Clark Atlanta University



PURPOSE

- An estimated 35,430 cases of prostate cancer are expected to be newly diagnosed among African-American men in 2015, accounting for 37% of all cancers diagnosed.
- It is estimated that 1 in 5 African-American men will be diagnosed with prostate cancer in his lifetime.
- The overall 5-year relative survival rate for prostate cancer among African Americans is 96%, compared to nearly 100% among whites.
- Prostate cancer patients are living longer and are confronted with increasingly complex therapeutic decisions.
- Frequently, patients are not fully prepared to discuss the possible treatment options effectively with their provider.

DESIGN METHODS

- The Center for Cancer Research and Therapeutic Development (CCRTD) at Clark Atlanta University (CAU) established the Prostate Cancer Registry an online registry www.pcregistry.cau.edu.
- The online self-reported registry is designed to provide prostate cancer survivors a unified voice to advance the understanding and challenges that universally affect survivors.
- Registrants were recruited through an outreach program that included the CCRTD, community-based affiliates, online communities, other advocacy organizations, & social and other media channels.
- In, 2015 close to 200 prostate cancer survivors completed the survey about their epidemiological profile, clinical disease information and data regarding their experiences throughout their prostate cancer continuum.


RESULTS

Sample Characteristics


Median Age	66 (SD = 9.979)
Married	78%
Ethnicity	59% White or Caucasian 36% Black or African American
Education	46% College 4 years or more 30% Graduate School
Insured	94%
Annual Household Income:	25% \$50K-74K 14% \$75K - \$99K

Treatment Decision Making


Did you receive any of the following **information** from your healthcare team **prior** to making your treatment decisions?




How **knowledgeable** were you about your treatment options **prior** to making your treatment decisions?




Did you receive any **treatment decision support** **prior** to making your treatment decisions?



Would you have liked more **support prior** to making your treatment decisions?




How much time do you feel you had to make a treatment decision?



RESULTS

When you were discussing your treatment options, did a member of your health care team speak to you about **cancer clinical trials**?



CONCLUSION

- Although the majority of the sample were satisfied with various aspects of treatment decision-making, including communication about treatment decisions with their healthcare team, more than half of the prostate cancer patients did not have a member of their healthcare team speak to them about cancer clinical trials.
- While most survivors reported receiving information about their treatment options, half of these individuals reported that they would have liked more support prior to making treatment decisions.
- Further efforts need to address gaps in the delivery of treatment decision support to prostate cancer patients.

ACKNOWLEDGEMENTS

This project is supported by the National Institute on Minority Health and Health Disparities (NIMHD) of the National Institutes of Health (NIH), in partnership with award number U54MD008621-01, sub-award with Hampton University.